METX logo

ME Therapeutics Holdings CNSX:METX Stock Report

Last Price

CA$3.80

Market Cap

CA$89.8m

7D

8.6%

1Y

3,700.0%

Updated

02 Dec, 2024

Data

Company Financials

ME Therapeutics Holdings Inc.

CNSX:METX Stock Report

Market Cap: CA$89.8m

METX Stock Overview

A preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno-oncology. More details

METX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

ME Therapeutics Holdings Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for ME Therapeutics Holdings
Historical stock prices
Current Share PriceCA$3.80
52 Week HighCA$7.50
52 Week LowCA$0.26
Beta0
11 Month Change-30.91%
3 Month Change153.33%
1 Year Change3,700.00%
33 Year Changen/a
5 Year Changen/a
Change since IPO520.41%

Recent News & Updates

Recent updates

Shareholder Returns

METXCA BiotechsCA Market
7D8.6%8.5%0.5%
1Y3,700.0%13.2%22.2%

Return vs Industry: METX exceeded the Canadian Biotechs industry which returned 13.2% over the past year.

Return vs Market: METX exceeded the Canadian Market which returned 22.2% over the past year.

Price Volatility

Is METX's price volatile compared to industry and market?
METX volatility
METX Average Weekly Movement75.2%
Biotechs Industry Average Movement11.5%
Market Average Movement8.4%
10% most volatile stocks in CA Market17.8%
10% least volatile stocks in CA Market3.0%

Stable Share Price: METX's share price has been volatile over the past 3 months compared to the Canadian market.

Volatility Over Time: METX's weekly volatility has increased from 49% to 75% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2014n/aSalim Dhanjiwww.metherapeutics.com

ME Therapeutics Holdings Inc., a preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno-oncology. Its lead candidate, h1B11-12, is a glycoprotein cytokine antibody drug that targets a key protein involved in the generation of suppressive myeloid cells for the treatment of colorectal cancer. The company also develops D094 and D099, which are small molecule myeloid targeted prodrug candidates to treat cancer; and myeloid targeting lipid nanoparticles (LNPS) formulations.

ME Therapeutics Holdings Inc. Fundamentals Summary

How do ME Therapeutics Holdings's earnings and revenue compare to its market cap?
METX fundamental statistics
Market capCA$89.81m
Earnings (TTM)CA$0
Revenue (TTM)n/a

n/a

P/E Ratio

n/a

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
METX income statement (TTM)
RevenueCA$0
Cost of RevenueCA$0
Gross ProfitCA$0
Other ExpensesCA$0
EarningsCA$0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)0
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did METX perform over the long term?

See historical performance and comparison